Skip to main content
      How do we manage difficult discussions about pregnancy in RA?

      Most rheums know that it is important to get pregnancy p

      Dr. John Cush RheumNow

      1 year ago
      How do we manage difficult discussions about pregnancy in RA? Most rheums know that it is important to get pregnancy planning right for women of childbearing age living with rheumatic diseases. That is easier said than done, though... https://t.co/cXtqqVv6fp https://t.co/k5afTUKYf8
      L20 at #ACR23

      Phase 3 RCT of #Telitacicept vs. placebo in #RA
      ☝🏻B-cell neutralization by targeting BlyS and APRIL

      ARD & RMD Open ARD_BMJ

      1 year ago
      L20 at #ACR23 Phase 3 RCT of #Telitacicept vs. placebo in #RA ☝🏻B-cell neutralization by targeting BlyS and APRIL ✅ better ACR20 and 50 response at W24 ✅ favorable structural response ✅ good safety profile ❓ few seronegative patients A new small molecule to treat #RA? PAJ https://t.co/fyrqAya41e
      #ACR23 #EdLovering presenting on association b/w #RA, #CVD & #Dementia:
      👉🏻CVD is not a signif mediator b/w RA

      Elena MyasoedovaMD ☀️

      1 year ago
      #ACR23 #EdLovering presenting on association b/w #RA, #CVD & #Dementia: 👉🏻CVD is not a signif mediator b/w RA &Dementia 👉🏻 signif synergy b/w RA & CVD on dementia (HR 2.45 vs those w/o RA&CVD) 👉🏻 ⬆️ risk of dementia in RA mostly in people with RA+CVD #Mayoclinicrheumatology https://t.co/5kqs3HAACn
      The dynamic Dr. Vinod Chandran, talking about metabolomics in #psoriaticDisease
      #ACR23
      The metabolomics facility was es

      Nigil Haroon MD, PhD, DM, FRCPC, FRCP, MBA NigilHaroon

      1 year ago
      The dynamic Dr. Vinod Chandran, talking about metabolomics in #psoriaticDisease #ACR23 The metabolomics facility was established recently at the @UHN @UofT @SchroederInst and we are already seeing the results. @KrembilF @CRASCRRheum @UofTRheum https://t.co/Azxq3k8w5g
      Impressive and important study supporting safety of TNF inhibitors among patients with RA-ILD. Elegant methods of target

      Jeffrey Sparks MD MMSc jeffsparks

      1 year ago
      Impressive and important study supporting safety of TNF inhibitors among patients with RA-ILD. Elegant methods of target trial emulation. Congrats to the authors on plenary presentation! #ACR23 https://t.co/P7keAoOX7M
      🔥 HOT OFF THE PRESS for #ACR23

      Effectiveness of a fourth dose of #COVID19 mRNA #vaccine in patients with systemic a

      The Lancet Rheumatology TheLancetRheum

      1 year ago
      🔥 HOT OFF THE PRESS for #ACR23 Effectiveness of a fourth dose of #COVID19 mRNA #vaccine in patients with systemic autoimmune rheumatic diseases using DMARDs: an emulated target trial https://t.co/bvc75BP4aG @zach_wallace_md @jeffsparks https://t.co/CAlgjvUr9X
      Something to listen to on the way home from #ACR23

      The last episode in a 4 part series on the environment and autoimmu

      Adam J Brown

      1 year ago
      Something to listen to on the way home from #ACR23 The last episode in a 4 part series on the environment and autoimmunity What does silica exposure have to do with autoimmunity? https://t.co/2Vqi22xqCw
      Nipocalimab (say it a couple of times) is a FcRn (neonatal Fc receptor) inhibitor. In short promotes degradation of IgG

      Tue Kragstrup KragstrupTW

      1 year ago
      Nipocalimab (say it a couple of times) is a FcRn (neonatal Fc receptor) inhibitor. In short promotes degradation of IgG incl autoantibodies (and investigated in myasthenia). Prof Taylor presents that it might work in CCP high titer RA at #ACR23. #ACRambassador @ACRheum https://t.co/DqlsOv7AVI
      Reminder of data for dose reduction #bDMARD by Prof Emery #ACR23

      Feasible after early remission induction https://t.co/

      Dr Gurdeep S Dulay

      1 year ago
      Reminder of data for dose reduction #bDMARD by Prof Emery #ACR23 Feasible after early remission induction https://t.co/WwiNp8WKDC
      Thanks #ACR23 for a wonderful meeting ! Presented a really positive phase 2 clinical trial results of Dazukibart, an IFN

      Rohit Aggarwal

      1 year ago
      Thanks #ACR23 for a wonderful meeting ! Presented a really positive phase 2 clinical trial results of Dazukibart, an IFN beta monoclonal antibody in #Myositis (DM) #pfizer .Strong efficacy with rapid onset. Safe & tolerable monthly IV injection. Looking forward to start Phase 3. https://t.co/580ICHM8Hs
      Just presented at #ACR23 by Dr Jennifer Hanberg @Jen_LS_Hanberg and published at @TheLancetRheum.!

      Effectiveness of 4

      Jeffrey Sparks MD MMSc jeffsparks

      1 year ago
      Just presented at #ACR23 by Dr Jennifer Hanberg @Jen_LS_Hanberg and published at @TheLancetRheum.! Effectiveness of 4th mRNA COVID dose on breakthrough infection @zach_wallace_md https://t.co/PXc2THn217
      Chikungunya - takeaway points

      🪔Acute arthritis in large joints , polyarthritis and tenosynovitis in hands
      🪔 Assoc

      Tanmayee Bichile, MD

      1 year ago
      Chikungunya - takeaway points 🪔Acute arthritis in large joints , polyarthritis and tenosynovitis in hands 🪔 Associated with travel history to Africa/Asia/Asia Pacific 🪔<5% develop chronic arthritis #ACR23 #ACRambassador https://t.co/yzZDpy70i3
      Maintain Vigilance for CV Risk Postpartum in Autoimmune Diseases

      Pregnant women with ARDs and APS face significantly i

      Dr. John Cush RheumNow

      1 year ago
      Maintain Vigilance for CV Risk Postpartum in Autoimmune Diseases Pregnant women with ARDs and APS face significantly increased risks of CVEs. This increased risk is often attributed to ARDs, its medications or comorbidities associated with it. https://t.co/KwMEwlr7Af https://t.co/vDt4B8jtt6
      Look if I’m going to be rheumatology writing on a Wednesday night in LA post-#ACR23 then it might as well be with a bu

      David Liew drdavidliew

      1 year ago
      Look if I’m going to be rheumatology writing on a Wednesday night in LA post-#ACR23 then it might as well be with a bulgogi cheesesteak (loaded with jalapeño) and a negroni @MamaShelterLA https://t.co/OsqKb2EkET